Literature DB >> 21529990

Re-appraisal of N2 disease by lymphatic drainage pattern for non-small-cell lung cancers: by terms of nodal stations, zones, chains, and a composite.

Hui Zheng1, Lin-mao Wang, Fang Bao, Ge-ning Jiang, Hui-kang Xie, Jia-an Ding, Xue-fei Hu, Chang Chen.   

Abstract

PURPOSE: N2 non-small-cell lung cancer (NSCLC) is a heterogeneous disease with an extremely wide range of 5-year survival rates. A composite method of sub-classification for N2 is likely to provide a more accurate method to more finely differentiate prognosis of N2 disease.
METHODS: A total of 720 pN2 (T1-4N2M0) NSCLC cases were enrolled in our retrospective analysis of the proposed composite method. Survival rates were respectively calculated according to the N2 stratification methods: singly by "nodal stations", "nodal zones", or "nodal chains", or by combination of all three. Statistical analysis was carried out by Kaplan-Meier and Cox regression models.
RESULTS: A total of 10,199 lymph nodes (8059 mediastinal; 2140 hilar and intra-lobar) were removed. By nodal station, there were 173 cases of single-station involvement and 547 multi-stations. By nodal zone, there were 413 single-zone involvement and 307 with multiple zones. By nodal chain, there were 311 cases with single-chain and 409 multi-chain involvements. The overall 5-year survival was 20% and median survival time was 27.52 months. The 5-year survival was significantly better for cases of single-zone involvement, as compared to multi-zones (29% vs. 6%, p<0.0001). The 5-year survival rates of single- and multi-chains involvement were 36% and 8%, respectively (p<0.0001). When taking all of the above grouping methods into consideration, the N2 disease state could be further sub-classified into two subgroups with respective survival rates of 36% and 7% (p<0.0001). Subgroup I was composed of individuals with single-chain involvement and having either one or two station metastasis; individuals with any other metastasis combinations formed Subgroup II. Multivariate analysis revealed that the composite sub-classification method, number of positive lymph nodes, ratio of nodal metastasis, and pT information were the most important risk factors of 5-year survival.
CONCLUSIONS: By combining the three N2 stratification methods based on "stations", "zones", and "chains" into one composite method, prognosis prediction was more accurate for N2 NSCLC disease. Single nodal chain involvement, which may be either one or two nodal stations metastasis, is associated with best outcome for pN2 patients.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21529990     DOI: 10.1016/j.lungcan.2011.03.020

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  10 in total

1.  The impact of positive nodal chain ratio on individualized multimodality therapy in non-small-cell lung cancer.

Authors:  Qinchen Cao; Baozhong Zhang; Lujun Zhao; Changli Wang; Liqun Gong; Jun Wang; Qingsong Pang; Kai Li; Weishuai Liu; Xue Li; Peng Wang; Ping Wang
Journal:  Tumour Biol       Date:  2015-01-27

2.  Selective mediastinal lymphadenectomy without intraoperative frozen section examinations for clinical stage I non-small-cell lung cancer: retrospective study of 403 cases.

Authors:  Wei Jiang; Xiaoke Chen; Junjie Xi; Qun Wang
Journal:  World J Surg       Date:  2013-02       Impact factor: 3.352

3.  Survival impact of node zone classification in resected pathological N2 non-small cell lung cancer.

Authors:  Tetsuro Baba; Hidetaka Uramoto; Taiji Kuwata; Yasuhiro Chikaishi; Makoto Nakagawa; Tomoko So; Takeshi Hanagiri; Fumihiro Tanaka
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-02-27

4.  Prognostic analysis of the bronchoplastic and broncho-arterioplastic lobectomy of non-small cell lung cancers-10-year experiences of 161 patients.

Authors:  Li-Lan Zhao; Fang-Yu Zhou; Chen-Yang Dai; Yi-Jiu Ren; Ge-Ning Jiang; Ke Fei; Chang Chen
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

5.  Prognostic role of station 3A mediastinal nodes for non-small-cell lung cancers.

Authors:  Hui Zheng; Wen Gao; Ke Fei; Hui-Kang Xie; Ge-Ning Jiang; Jia-An Ding; Chao Li; Chang Chen; Lei Zhang
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-06-19

6.  Spanish Lung Cancer Group SCAT trial: surgical audit to lymph node assessment based on IASLC recommendations.

Authors:  José Ramón Jarabo Sarceda; Sergio Bolufer Nadal; Roberto Mongil Poce; Pedro López de Castro; Ramón Moreno Balsalobre; Juan Carlos Peñalver Cuesta; Raul Embún Flor; Joaquín Pac Ferrer; Francisco Javier Algar Algar; Antonio Pablo Gámez García; Marcelo F Jiménez; Jesús Gabriel Sales-Badía; Eva Pereira; Bartomeu Massuti; Mariano Provencio; Florentino Hernando Trancho
Journal:  Transl Lung Cancer Res       Date:  2021-04

7.  Proposal of a new nodal classification for operable non-small cell lung cancer based on the number of negative lymph nodes and the anatomical location of metastatic lymph nodes.

Authors:  Hongfeng Liu; Tao Yan; Tiehong Zhang; Xiaowei Chen; Yadong Wang; Jiajun Du
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

8.  Numbers and Stations: Impact of Examined Lymph Node on Precise Staging and Survival of Radiologically Pure-Solid NSCLC: A Multi-Institutional Study.

Authors:  Donglai Chen; Yiming Mao; Junmiao Wen; Jian Shu; Fei Ye; Yunlang She; Qifeng Ding; Li Shi; Tao Xue; Min Fan; Yongbing Chen; Chang Chen
Journal:  JTO Clin Res Rep       Date:  2020-03-23

9.  High dose involved field radiation therapy as salvage for loco-regional recurrence of non-small cell lung cancer.

Authors:  Sun Hyun Bae; Yong Chan Ahn; Heerim Nam; Hee Chul Park; Hong Ryull Pyo; Young Mog Shim; Jhingook Kim; Kwhanmien Kim; Jin Seok Ahn; Myung-Ju Ahn; Keunchil Park
Journal:  Yonsei Med J       Date:  2012-11-01       Impact factor: 2.759

Review 10.  Prognostic factors in resected lung carcinomas.

Authors:  Keith M Kerr; Marianne C Nicolson
Journal:  EJC Suppl       Date:  2013-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.